Novartis AG
US.NVS
159.99
-3.10
-1.90%
Novartis AG
159.99
-3.10
-1.90%
Live - 104 symbols - heartbeat 132s ago
· 2026-09-04 20:02
Pre-market
159.89
-1.96%
After-hours
152.50
-4.68%
Overnight
161.48
-0.99%
Revenue annual, last 8 years
Margins
- Gross margin
- 75.83%
- Operating margin
- 31.13%
- Net margin
- 24.67%
Key ratios & quality
- Enterprise value
- 326.28B
- PEG ratio
- 0.92
PEG uses trailing P/E against the 3-year net income growth rate (26.22%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG."
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | 31.59B | 34.25B | 34.78B | 32.24B | 31.88B | 34.19B | 38.90B | 42.98B |
| Selling & admin expenses | 13.72B | 14.37B | 14.20B | 12.83B | 12.19B | 12.52B | 12.57B | 13.25B |
| Research & development | 8.49B | 9.40B | 8.98B | 8.64B | 9.17B | 11.37B | 10.02B | 11.20B |
| Operating profit | 8.40B | 9.09B | 10.15B | 10.06B | 7.95B | 9.77B | 14.54B | 17.64B |
| Pretax profit | 14.10B | 8.94B | 9.88B | 24.53B | 7.18B | 9.12B | 13.64B | 16.35B |
| Tax | 1.30B | 1.79B | 1.81B | 1.63B | 1.13B | 551.00M | 1.70B | 2.39B |
| Net profit | 12.61B | 11.74B | 8.07B | 24.02B | 6.96B | 14.85B | 11.94B | 13.97B |
| Basic EPS | 5 | 5 | 4 | 11 | 3 | 7 | 6 | 7 |
| Diluted EPS | 5.38 | 5.06 | 3.52 | 10.63 | 3.17 | 7.10 | 5.87 | 7.15 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | 10.39B | 11.51B | 10.82B | 10.25B | 10.07B | 11.24B |
| Selling & admin expenses | 3.06B | 3.44B | 3.31B | 3.44B | 3.14B | 3.24B |
| Research & development | 2.37B | 2.73B | 2.94B | 3.16B | 2.74B | 2.85B |
| Operating profit | 4.66B | 4.86B | 4.50B | 3.62B | 4.24B | 4.75B |
| Pretax profit | 4.41B | 4.53B | 4.20B | 3.22B | 3.84B | 4.27B |
| Tax | 798.00M | 507.00M | 266.00M | 814.00M | 683.00M | 1.01B |
| Net profit | 3.61B | 4.02B | 3.93B | 2.40B | 3.16B | 3.26B |
| Basic EPS | 2 | 2 | 2 | 1 | 2 | 2 |
| Diluted EPS | 1.82 | 2.06 | 2.02 | 1.25 | 1.65 | 1.71 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 35.56B | 29.50B | 29.67B | 45.72B | 36.91B | 30.48B | 29.70B | 30.46B |
| Cash & ST investments | 15.73B | 11.23B | 11.29B | 28.11B | 18.62B | 13.96B | 13.35B | 11.53B |
| Inventory | 6.96B | 5.98B | 7.13B | 6.67B | 7.18B | 5.91B | 5.72B | 6.27B |
| Total assets | 145.56B | 118.37B | 127.78B | 131.80B | 117.45B | 99.95B | 102.25B | 110.95B |
| Total current liabilities | 29.61B | 28.26B | 33.06B | 30.21B | 28.66B | 26.39B | 28.69B | 27.28B |
| Short-term debt | 9.62B | 7.09B | 9.88B | 6.50B | 6.13B | 6.31B | 8.32B | 5.78B |
| Long-term debt | 22.47B | 20.35B | 26.26B | 22.90B | 20.24B | 18.44B | 21.37B | 27.94B |
| Total liabilities | 66,871,000,000.00 | 62,819,000,000.00 | 71,112,000,000.00 | 63,973,000,000.00 | 58,030,000,000.00 | 53,195,000,000.00 | 58,120,000,000.00 | 64,400,000,000.00 |
| Total equity | 78.69B | 55.55B | 56.67B | 67.82B | 59.42B | 46.75B | 44.13B | 46.55B |
| Retained earnings | 82.19B | 59.28B | 57.16B | 70.99B | 63.54B | 49.65B | 46.56B | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 25.11B | 25.94B | 28.20B | 30.46B | 26.61B | 27.35B |
| Cash & ST investments | 7.20B | 7.00B | 9.75B | 11.53B | 6.98B | 7.69B |
| Inventory | 5.83B | 6.31B | 6.42B | 6.27B | 6.29B | 6.22B |
| Total assets | 99.94B | 104.40B | 107.29B | 110.95B | 118.53B | 122.03B |
| Total current liabilities | 31.62B | 31.71B | 32.00B | 27.28B | 31.37B | 31.75B |
| Short-term debt | 8.04B | 8.57B | 7.78B | 5.78B | 7.89B | 9.86B |
| Long-term debt | 21.67B | 22.47B | 22.60B | 27.94B | 37.45B | 37.49B |
| Total liabilities | 61,489,000,000.00 | 62,341,000,000.00 | 62,537,000,000.00 | 64,400,000,000.00 | 79,605,000,000.00 | 80,087,000,000.00 |
| Total equity | 38.45B | 42.05B | 44.75B | 46.55B | 38.93B | 41.95B |
| Retained earnings | 39.84B | 41.53B | 43.51B | -- | 37.25B | 39.65B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 14.27B | 13.63B | 13.65B | 15.07B | 14.24B | 14.46B | 17.62B | 19.14B |
| Depreciation & amortization | 5.21B | 5.83B | 6.46B | 5.60B | 6.71B | 8.28B | 6.07B | 5.33B |
| Free cash flow | 11.62B | 11.37B | 11.07B | 12.52B | 12.00B | 11.71B | 13.81B | 15.24B |
| Dividends paid | -6.97B | -6.65B | -6.99B | -7.37B | -7.51B | -7.26B | -7.62B | -7.82B |
| Stock buybacks / issuance | -2.04B | -5.53B | -2.84B | -3.06B | -10.65B | -8.72B | -8.33B | -9.21B |
| Ending cash balance | 13.27B | 11.11B | 9.66B | 12.41B | 7.52B | 13.39B | 11.46B | 11.44B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 3.65B | 6.66B | 6.57B | 2.26B | 3.68B | 5.88B |
| Depreciation & amortization | 1.15B | 1.26B | 1.36B | 1.55B | 1.23B | 1.40B |
| Free cash flow | 2.15B | 6.11B | 5.74B | 1.25B | 2.87B | 5.12B |
| Dividends paid | -5.33B | -2.49B | -- | 0 | -6.20B | -2.87B |
| Stock buybacks / issuance | -2.72B | -2.71B | -2.30B | -1.48B | -1.88B | -1.20B |
| Ending cash balance | 7.07B | 6.66B | 9.56B | 11.44B | 6.88B | 7.62B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE % | 16.51 | 17.50 | 14.41 | 38.66 | 10.95 | 28.02 | 26.33 | 31.01 |
| ROA % | 9.05 | 8.89 | 6.45 | 18.21 | 5.58 | 13.66 | 11.81 | 13.12 |
| ROIC % | 12.39 | 12.51 | 9.73 | 25.58 | 7.89 | 18.80 | 16.62 | 18.68 |
| 5-year avg ROE % | 14.76 | 15.45 | 13.52 | 19.48 | 19.61 | 21.91 | 23.67 | 27.00 |
| EBIT margin % | 27.82 | 20.11 | 21.54 | 50.96 | 17.77 | 21.38 | 28.32 | 30.87 |
| FCF / sales % | 20.53 | 23.35 | 22.18 | 22.88 | 22.31 | 25.09 | 26.69 | 26.90 |
| Current ratio | 1.20 | 1.04 | 0.90 | 1.51 | 1.29 | 1.16 | 1.04 | 1.12 |
| Quick ratio | 0.90 | 0.76 | 0.65 | 1.25 | 0.99 | 0.88 | 0.79 | 0.82 |
| Debt / assets | 40.82 | 52.54 | 66.88 | 45.86 | 47.03 | 56.46 | 70.97 | 76.69 |
| LT debt / equity | 28.58 | 39.76 | 49.43 | 36.25 | 36.71 | 42.93 | 52.07 | 64.15 |
| Interest coverage | 15.46 | 11.52 | 12.37 | 33.23 | 11.00 | 11.67 | 14.56 | 15.29 |
| Revenue CAGR (3Y) % | -2.92 | -0.51 | 4.76 | -1.56 | -3.71 | -2.21 | 5.56 | 9.25 |
| Net income CAGR (3Y) % | -10.82 | 20.46 | 1.57 | 23.96 | -15.99 | 22.53 | -20.78 | 26.22 |
| FCF CAGR (3Y) % | 11.47 | 9.76 | 2.33 | 2.49 | 1.81 | 1.89 | 3.32 | 8.31 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE % | 32.95 | 32.62 | 32.84 | 31.01 | 35.21 | 30.55 |
| ROA % | 13.24 | 13.53 | 13.65 | 13.12 | 12.39 | 11.27 |
| ROIC % | 20.16 | 20.11 | 20.25 | 18.68 | 18.79 | 16.83 |
| 5-year avg ROE % | -- | -- | -- | -- | -- | -- |
| EBIT margin % | 30.01 | 30.27 | 31.10 | 30.87 | 30.05 | 29.83 |
| FCF / sales % | 27.90 | 30.45 | 30.26 | 26.90 | 28.21 | 26.42 |
| Current ratio | 0.79 | 0.82 | 0.88 | 1.12 | 0.85 | 0.86 |
| Quick ratio | 0.50 | 0.51 | 0.59 | 0.82 | 0.53 | 0.55 |
| Debt / assets | 81.50 | 77.73 | 72.24 | 76.69 | 122.03 | 117.99 |
| LT debt / equity | 60.54 | 57.32 | 54.68 | 64.15 | 101.55 | 94.25 |
| Interest coverage | 15.14 | 15.21 | 15.73 | 15.29 | 13.97 | 12.17 |
| Revenue CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research, development, manufacturing, distribution, marketing and sale of a broad range of100.00%
Quote time 2026-09-04 20:02:17
For reference only, not investment advice.